Related Experiment Video
Updated: Feb 20, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.3K
Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences
Frank R Wendt1,2, Antti Sajantila3, Rodrigo S Moura-Neto4
1Center for Human Identification, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., CBH-250, Fort Worth, TX, 76107, USA. Frank.Wendt@my.unthsc.edu.
International Journal of Legal Medicine
|October 28, 2017
Summary
New CYP2D6 gene analysis reveals rare variants impacting drug metabolism. This pharmacogenetic research improves metabolizer phenotype prediction, crucial for personalized medicine and forensic toxicology.
Area of Science:
- Pharmacogenetics
- Genomic Medicine
- Forensic Toxicology
Background:
- Cytochrome P450 2D6 (CYP2D6) is vital for drug metabolism, with genetic variations influencing enzyme activity and predicting metabolizer phenotypes (poor, intermediate, normal, ultrarapid).
- Current genotyping methods for CYP2D6 are limited to known polymorphisms, potentially overlooking novel or rare variants that affect enzyme function.
- Accurate CYP2D6 phenotype prediction is essential for personalized drug therapy and can aid in forensic investigations.
Purpose of the Study:
- To identify and characterize novel and rare CYP2D6 polymorphisms using comprehensive sequencing data.
- To generate full-gene haplotypes for CYP2D6 and assess their distribution across populations.
- To predict enzyme activity scores based on these extended haplotypes and compare them with current methods.
Main Methods:
- Utilized the 1000 Genomes Project dataset for comprehensive analysis of the CYP2D6 gene.
- Generated full-gene haplotypes encompassing known and newly identified polymorphisms.
- Calculated predicted enzyme activity scores for identified haplotypes.
- Assessed the distribution of these haplotypes across global super-populations.
Main Results:
- Full-gene haplotype analysis identified additional polymorphisms impacting CYP2D6 enzyme function not included in current star allele definitions.
- Predicted enzyme activity scores were generally lower with full-gene haplotypes compared to conventional approaches.
- A subset of individuals may be misclassified as normal metabolizers due to the exclusion of these additional damaging variants.
Conclusions:
- Current CYP2D6 star allele nomenclature may underestimate the prevalence of poor and intermediate metabolizers.
- Incorporating full-gene haplotypes into clinical practice can lead to more accurate pharmacogenetic predictions.
- Improved CYP2D6 phenotyping has significant implications for optimizing drug efficacy and safety, and for forensic applications.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
01:27Pharmacogenetics of Drug Metabolism: Overview
23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
01:27Principles of Pharmacogenetics: Types of Genetic Variants
22
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
22
01:29Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
16
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
16